摘要
血管生成是一种极其复杂的生物学过程,它在各种肿瘤生长和转移中起着重要作用,除此之外,抗血管内皮生长因子显著升高还与视网膜血管性疾病的发生发展密切相关。贝伐珠单抗是首次被批准用于晚期非小细胞肺癌一线治疗的血管生成抑制剂。已有部分临床试验、系统评价及Meta分析发现贝伐珠单抗在目前国家药品监督管理局批准之外的适应证有治疗作用。经查询国内外网站贝伐珠单抗的最新版药品说明书、权威指南和诊疗规范,收集贝伐珠单抗的全部适应证,计算机检索PubMed、CNKI和万方数据库,检索时限为从建库至2022年12月,收集贝伐珠单抗治疗各种癌症的超说明书用药研究文献,形成贝伐珠单抗超说明书用药专家共识,以期为临床用药提供参考。
Angiogenesis is an extremely complex biological process,which plays an important role in the growth and metastasis of various tumors,besides,the significant increase of anti-vascular endothelial growth factor is closely related to the pathogenesis and development of retinal vascular disease.Bevacizumab is the first angiogenesis inhibitor approved for first-line treatment of advanced non-small cell lung cancer.Some clinical trials,systematic reviews and meta-analysis have found that bevacizumab has therapeutic effects in indications other than those currently approved by the National Medical Products Administration.All indications of bevacizumab were gathered by querying the latest edition of bevacizumab instructions,authoritative guidelines and diagnosis and treatment specifications on domestic and foreign websites.The off-label drug use research literature of bevacizumab in the treatment of various cancers was collected by searching in PubMed,CNKI,Wanfang Database from the establishment of the database to December 2022.The expert consensus on off-label drug use of bevacizumab was finally formed in order to provide reference for clinical medication.
出处
《中国现代应用药学》
CAS
CSCD
北大核心
2024年第17期2388-2395,共8页
Chinese Journal of Modern Applied Pharmacy
基金
浙江省自然科学基金项目(LYY22H300003)。
